Showing results (681-690 of 708) with videos related to
Sort By:
Pageof 71
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.Biorxiv : the Preprint Server for Biology|July 14, 2025
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosisJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.BMC Genomics|December 26, 2008
A first generation whole genome RH map of the river buffalo with comparison to domestic cattleM Elisabete J Amaral, Jason R Grant, Penny K Riggs, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.Journal of Inherited Metabolic Disease|October 29, 2011
Mutation analysis in 54 propionic acidemia patientsJ P Kraus, E Spector, S Venezia, et al.Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.Pageof 71